2024 marks the occasion of the 20th annual biosimilar medicines conference. Since its first edition, the conference has been the stage of vivid multi-stakeholders debates and discussions. Year-on-year, it has provided the opportunity to hear for EU and international experts and witness the unfolding of a regulatory-science success story and more importantly, a story where patients and healthcare professionals have observed and realised,
the significant health value smart biosimilar medicines policy can bring (over 5.8bn patient treatment days of safe clinical use) while contributing to the sustainability and resilience of healthcare system (€50bn cumulated savings since 2006, €10bn in 2023 alone).

Open